Skip to main content
Clinical Trials/NCT05379348
NCT05379348Active, not recruitingNot Applicable

Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease

AdventHealth Translational Research Institute1 site in 1 country1,423 target enrollmentStarted: March 14, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
1,423
Locations
1
Primary Endpoint
Quantify the proportion of individuals at least 65 years old with cognitive impairment

Study Overview

Brief Summary

The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Quantify the proportion of individuals at least 65 years old with cognitive impairment

Time Frame: Less than 6 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
AdventHealth Translational Research Institute
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials